Cargando…

Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis

INTRODUCTION: Pasireotide (PAS) is a novel somatostatin receptor ligands (SRL), used in controlling hormonal hypersecretion in both acromegaly and Cushing’s Disease (CD). In previous studies and meta-analysis, first-generation SRLs were reported to be able to induce significant tumor shrinkage only...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondin, Alessandro, Manara, Renzo, Voltan, Giacomo, Tizianel, Irene, Denaro, Luca, Ferrari, Marco, Barbot, Mattia, Scaroni, Carla, Ceccato, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283714/
https://www.ncbi.nlm.nih.gov/pubmed/35846311
http://dx.doi.org/10.3389/fendo.2022.935759
_version_ 1784747386530168832
author Mondin, Alessandro
Manara, Renzo
Voltan, Giacomo
Tizianel, Irene
Denaro, Luca
Ferrari, Marco
Barbot, Mattia
Scaroni, Carla
Ceccato, Filippo
author_facet Mondin, Alessandro
Manara, Renzo
Voltan, Giacomo
Tizianel, Irene
Denaro, Luca
Ferrari, Marco
Barbot, Mattia
Scaroni, Carla
Ceccato, Filippo
author_sort Mondin, Alessandro
collection PubMed
description INTRODUCTION: Pasireotide (PAS) is a novel somatostatin receptor ligands (SRL), used in controlling hormonal hypersecretion in both acromegaly and Cushing’s Disease (CD). In previous studies and meta-analysis, first-generation SRLs were reported to be able to induce significant tumor shrinkage only in somatotroph adenomas. This systematic review and meta-analysis aim to summarize the effect of PAS on the shrinkage of the pituitary adenomas in patients with acromegaly or CD. MATERIALS AND METHODS: We searched the Medline database for original studies in patients with acromegaly or CD receiving PAS as monotherapy, that assessed the proportion of significant tumor shrinkage in their series. After data extraction and analysis, a random-effect model was used to estimate pooled effects. Quality assessment was performed with a modified Joanna Briggs’s Institute tool and the risk of publication bias was addressed through Egger’s regression and the three-parameter selection model. RESULTS: The electronic search identified 179 and 122 articles respectively for acromegaly and CD. After study selection, six studies considering patients with acromegaly and three with CD fulfilled the eligibility criteria. Overall, 37.7% (95%CI: [18.7%; 61.5%]) of acromegalic patients and 41.2% (95%CI: [22.9%; 62.3%]) of CD patients achieved significant tumor shrinkage. We identified high heterogeneity, especially in acromegaly (I(2) of 90% for acromegaly and 47% for CD), according to the low number of studies included. DISCUSSION: PAS treatment is effective in reducing tumor size, especially in acromegalic patients. This result strengthens the role of PAS treatment in pituitary adenomas, particularly in those with an invasive behavior, with progressive growth and/or extrasellar extension, with a low likelihood of surgical gross-total removal, or with large postoperative residual tissue. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022328152, identifier CRD42022328152
format Online
Article
Text
id pubmed-9283714
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92837142022-07-16 Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis Mondin, Alessandro Manara, Renzo Voltan, Giacomo Tizianel, Irene Denaro, Luca Ferrari, Marco Barbot, Mattia Scaroni, Carla Ceccato, Filippo Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: Pasireotide (PAS) is a novel somatostatin receptor ligands (SRL), used in controlling hormonal hypersecretion in both acromegaly and Cushing’s Disease (CD). In previous studies and meta-analysis, first-generation SRLs were reported to be able to induce significant tumor shrinkage only in somatotroph adenomas. This systematic review and meta-analysis aim to summarize the effect of PAS on the shrinkage of the pituitary adenomas in patients with acromegaly or CD. MATERIALS AND METHODS: We searched the Medline database for original studies in patients with acromegaly or CD receiving PAS as monotherapy, that assessed the proportion of significant tumor shrinkage in their series. After data extraction and analysis, a random-effect model was used to estimate pooled effects. Quality assessment was performed with a modified Joanna Briggs’s Institute tool and the risk of publication bias was addressed through Egger’s regression and the three-parameter selection model. RESULTS: The electronic search identified 179 and 122 articles respectively for acromegaly and CD. After study selection, six studies considering patients with acromegaly and three with CD fulfilled the eligibility criteria. Overall, 37.7% (95%CI: [18.7%; 61.5%]) of acromegalic patients and 41.2% (95%CI: [22.9%; 62.3%]) of CD patients achieved significant tumor shrinkage. We identified high heterogeneity, especially in acromegaly (I(2) of 90% for acromegaly and 47% for CD), according to the low number of studies included. DISCUSSION: PAS treatment is effective in reducing tumor size, especially in acromegalic patients. This result strengthens the role of PAS treatment in pituitary adenomas, particularly in those with an invasive behavior, with progressive growth and/or extrasellar extension, with a low likelihood of surgical gross-total removal, or with large postoperative residual tissue. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022328152, identifier CRD42022328152 Frontiers Media S.A. 2022-07-01 /pmc/articles/PMC9283714/ /pubmed/35846311 http://dx.doi.org/10.3389/fendo.2022.935759 Text en Copyright © 2022 Mondin, Manara, Voltan, Tizianel, Denaro, Ferrari, Barbot, Scaroni and Ceccato https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Mondin, Alessandro
Manara, Renzo
Voltan, Giacomo
Tizianel, Irene
Denaro, Luca
Ferrari, Marco
Barbot, Mattia
Scaroni, Carla
Ceccato, Filippo
Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
title Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
title_full Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
title_fullStr Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
title_full_unstemmed Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
title_short Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
title_sort pasireotide-induced shrinkage in gh and acth secreting pituitary adenoma: a systematic review and meta-analysis
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283714/
https://www.ncbi.nlm.nih.gov/pubmed/35846311
http://dx.doi.org/10.3389/fendo.2022.935759
work_keys_str_mv AT mondinalessandro pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis
AT manararenzo pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis
AT voltangiacomo pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis
AT tizianelirene pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis
AT denaroluca pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis
AT ferrarimarco pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis
AT barbotmattia pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis
AT scaronicarla pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis
AT ceccatofilippo pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis